Appointment of Nominated Adviser

RNS Number : 5484K

Immupharma PLC

17 December 2018

 

                                                                                                                                                                 17 December 2018

ImmuPharma PLC

("ImmuPharma" or the "Company")

APPOINTMENT OF NOMINATED ADVISOR

ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company is pleased to announce the appointment of SPARK Advisory Partners Limited ("SPARK") as the Company's Nominated Advisor ("NOMAD"), with immediate effect.

Commenting on the appointment, ImmuPharma's Chairman, Tim McCarthy, said:

"I am delighted to announce the appointment of SPARK as the Company's NOMAD. We look forward to working with the team going forward, alongside our joint brokers, Stanford Capital Partners and SI Capital."

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014. ("MAR")

For further information please contact: ImmuPharma plc (www.immupharma.com) + 44 (0) 207 152 4080 Tim McCarthy, Chairman Lisa Baderoon, Head of Investor Relations + 44 (0) 7721 413496 SPARK Advisory Partners Limited (NOMAD) Neil Baldwin Vassil Kirtchev Stanford Capital Partners (Joint Broker) Patrick Claridge, John Howes SI Capital (Joint Broker) Nick Emerson [phone] [phone] [phone] About SPARK Advisory Partners Limited SPARK Advisory Partners was established in January 2012 by its founding partners to provide product independent corporate finance advice to mid-market companies, owner managers and shareholders. SPARK is owned by its partners who have worked together for many years. The team has a broad cross section of skills and transaction experience, encompassing M&A, private equity, public capital raisings and debt advisory services. For more information go to: www.sparkadvisorypartners.com

 

END

 

 

APPBBBDDCBBBGIS